[Blood coagulation and fibrinolysis in patients treated with an anovulatory drug having an estroprogestational action].
D001695:Biology; D001769:Blood; D001777:Blood Coagulation; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D005193:Family Planning Services; D005342:Fibrinolysis; D008234:Lynestrenol; D008656:Mestranol; D010827:Physiology; D012106:Research
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D008656:Mestranol; D008234:Lynestrenol
Biology; Blood Coagulation Effects; Clinical Research; Contraception; Contraceptive Agents, Estrogen--side effects; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Family Planning; Fibrinolysis; Hematological Effects; Hemic System; Lynestrenol--side effects; Mestranol--side effects; Oral Contraceptives; Oral Contraceptives, Combined; Physiology; Research Methodology
Emocoagulazione e fibrinolisi in pazienti trattate con farmaco anovulatorio ad azione estroprogestinica.